- 期刊
慢性腎臟病貧血新藥：缺氧誘導因子脯氨醯羥化酶抑制劑
New Drugs for Anemia in Chronic Kidney Disease: Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
摘要
目前慢性腎臟病貧血治療主要為補充鐵劑、紅細胞生成刺激素（ESA）以及紅血球輸血，但有研究表明ESA可能增加心血管事件和死亡的風險，近來發展新一代口服貧血藥物：缺氧誘導因子脯胺酸羥化酶抑制劑（hypoxia-inducible factor prolyl hydroxylase inhibitors, HIF-PHI），目前已在一些國家核准上市，可刺激體內紅血球生成素生成及提高鐵的利用，臨床上希望以HIF-PHI口服製劑取代ESA針劑治療，以增加病人順從性、避免ESA的風險，未來可望成為貧血治療的新選擇，本篇文章統整介紹慢性腎臟病貧血定義、評估標準、藥物治療與近年發展的新藥HIF-PH抑制劑。
並列摘要
At present, anemia in chronic kidney disease is treated with iron supplementation, erythropoiesis-stimulating agents (ESAs), or red blood cell transfusions. Some studies suggest that ESAs may increase the risk of cardiovascular events and death. Recently, hypoxia-inducible factors prolyl hydroxylase inhibitors (HIF-PHIs) - the new generation of oral anemia drugs, have been approved in some countries. HIF-PHIs can stimulate erythropoietin production and improve iron utilization. HIF-PHI oral preparations are hoped to substitute the traditional ESA treatment to increase patient compliance and avoid ESA risk and are expected to become a new option for anemia treatment. This article presents an overview of the definition, evaluation criteria, current drug treatments, and newly developed HIF-PHs for anemia in chronic kidney disease.